title: Treatment of bioresorbable scaffold failure.
abstract: Bioresorbable scaffolds (BRS) are a promising new interventional treatment strategy for coronary artery disease (CAD). They are intended to overcome some of the shortcomings of metal drug-eluting stents (DES), mainly late reinterventions which occur at a consistent rate after one year and have not been reduced by the use of local drug elution. Initial experience in non-complex lesions established efficacy in opening the vessel and the concept of bioresorption. However, with the use of BRS in more complex lesions, the incidence of BRS failure, including both scaffold restenosis and thrombosis, has also increased. Therefore, understanding of both the pathophysiology and of the available treatment options of scaffold failure remains an important issue in ensuring procedural and long-term clinical success.
authors.affiliation: Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Cordula
authors.initials: C
authors.lastname: Felix
authors.forename: Bert
authors.initials: B
authors.lastname: Everaert
authors.forename: Nigel
authors.initials: N
authors.lastname: Jepson
authors.forename: Corrado
authors.initials: C
authors.lastname: Tamburino
authors.forename: Robert-Jan
authors.initials: RJ
authors.lastname: van Geuns
mesh_terms: D020341:Absorbable Implants; D015906:Angioplasty, Balloon, Coronary; D003324:Coronary Artery Disease / Q000601:surgery*; D023903:Coronary Restenosis / Q000453:epidemiology / Q000628:therapy*; D003328:Coronary Thrombosis / Q000453:epidemiology / Q000628:therapy*; D054855:Drug-Eluting Stents; D004868:Equipment Failure / Q000706:statistics & numerical data; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology / Q000628:therapy*; D012086:Reoperation; D012307:Risk Factors; D015607:Stents; D017131:Thrombectomy; D054457:Tissue Scaffolds
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors